Welcome to our dedicated page for XOMA Royalty news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty stock.
XOMA Royalty Corporation operates as a biotechnology royalty aggregator that acquires rights to potential milestone and royalty payments tied to therapeutic candidates licensed to pharmaceutical and biotechnology companies. Its updates commonly address portfolio additions, royalty-sharing transactions, commercial and development-stage assets, clinical and regulatory disclosures from underlying programs, and cash receipts from royalties and milestones.
Company news also covers financial results, preferred stock dividends on its Series A and Series B cumulative preferred securities, completed acquisitions that expand the royalty portfolio, and executive or governance changes. Named portfolio assets include VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, DARE to PLAY, DSUVIA, and development-stage assets such as mezagitamab.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 26, 2023, XOMA Corporation (NASDAQ: XOMA) announced that Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference. This event is scheduled for May 2, 2023, at 10:30 AM ET. Investors can access the chat through a link provided or via the investor relations section of XOMA's website. A replay of the discussion will be available for 90 days post-event.
XOMA operates as a biotechnology royalty aggregator, acquiring future economic rights tied to pre-commercial therapeutic candidates. With over 70 assets in its portfolio, it provides non-dilutive funding to biotech companies. For more information, visit www.xoma.com.
XOMA Corporation has acquired commercial payment and milestone rights for IXINITY® from Aptevo Therapeutics for $9.6 million, aimed at enhancing XOMA's cash flow and royalty aggregation strategy. IXINITY® is used for managing bleeding in Hemophilia B patients. XOMA will start receiving mid-single digit percentage payments from IXINITY® sales, beginning January 1, 2023, until the first quarter of 2035, along with additional milestone payments. This move underscores IXINITY's growth potential within its treatment niche.
XOMA Corporation (Nasdaq: XOMA) has announced cash dividends for its preferred stockholders. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive $0.53906 per share, while holders of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive $0.52344 per depositary share. The dividends will be paid on April 17, 2023, to shareholders on record by April 4, 2023. XOMA operates as a biotechnology royalty aggregator, managing a diverse portfolio of over 70 assets associated with pre-commercial therapeutic candidates. This strategic focus aids biotech firms in advancing their drug development while providing XOMA with potential financial returns.
XOMA Corporation (NASDAQ: XOMA) reported financial results for 2022, highlighting the acquisition of the Ebopiprant royalty, potentially generating up to $378 million in milestones and royalties from Organon. Revenues dropped to $6.0 million in 2022 compared to $38.2 million in 2021, mainly from milestone payments. The company’s general and administrative expenses increased significantly to $23.2 million, primarily due to salary increases and consulting costs. Notably, the net loss for 2022 reached $17.1 million. However, XOMA expects to generate cash flow from commercial assets, particularly Vabysmo®, with anticipated cash receipts of over $20 million to cover operating expenses in 2023.